Ardelyx was founded in 2007 by Dominique Charmot, Ph.D., Peter Schultz, Ph.D. and Jean Frechet, Ph.D., to develop a pipeline of next generation non and minimally-absorbed small molecule drugs.
Through a radical approach to drug discovery and development, Ardelyx has established a pipeline of novel, first-in-class drugs engineered to correct mineral metabolism imbalance and metabolic disorders.
These molecules, each of which has a unique mechanism of action, have been designed to modulate the function of specific transporters, channels, and receptors located on the epithelia (cells that line the surface) of the gastrointestinal (GI) tract.
A key attribute to the design of these drugs is that their systemic exposure is greatly restricted. This attribute reduces much of the risk of side effects that stifles the development of traditionally designed drugs. As a result, we enhance the safety of our drugs and, by extension, dramatically increase the probability of regulatory and commercial success.
Our products target chronic diseases affecting large populations, including hypertension, chronic kidney disease (CKD), diabetes, irritable bowel syndrome and other disorders.
In short, the targeted therapeutic activity of our drugs, coupled with their minimal systemic exposure, enables Ardelyx to establish a clear pathway for the rapid, cost-effective clinical development of novel therapeutics.